GZMB and metastatic malignant neoplasm in the lymph nodes: When comparing clinicopathological characteristics, the low GzmB/CCR8 ratio group from the ROI protocol had significantly higher rates of lymph node metastasis (34.1% vs. 12.5%, respectively, P = 0.035) and pleural invasion (22.0% vs. 5.0%, respectively, P = 0.048) (Table 1).